HALO
Halozyme Therapeutics, Inc. · Healthcare
Director Matthew L. Posard sold $1.0M of Halozyme Therapeutics, Inc.
Sold$1,006,300
$50.32Price
20,000Shares
−17%Stake
What HALO did after the filing
- The stock from Fri, Jun 14 open, $49.10
- +13.4%
- S&P 500, same days
- +0.5%
Measured over 30 trading days, to the Jul 30 close.
Traded Tue, Jun 11. Filed Thu, Jun 13, 4:15 PM ET, after the close. Returns use the Jun 14 open and the Jul 30 close. Not investment advice.